Page last updated: 2024-11-13

atpenin a5

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

atpenin A5: from Penicillium sp. FO-125; MW C15-H21-N-O5-Cl2 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54676868
CHEMBL ID1081615
SCHEMBL ID1506735
SCHEMBL ID20472249
MeSH IDM0162588

Synonyms (21)

Synonym
AT5 ,
atpenin a5
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethyl-1-oxohexyl]-4-hydroxy-5,6-dimethoxy-2(1h)-pyridinone
DB04631
CHEMBL1081615
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-2-hydroxy-5,6-dimethoxy-1h-pyridin-4-one
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1h-pyridin-2-one
119509-24-9
SCHEMBL1506735
HB3783
c15h21cl2no5
DTXSID60152478
J-004142
SCHEMBL20472249
atpenin a5; aa5
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxypyridin-2(1h)-one
Q27095367
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1,2-dihydropyridin-2-one
AS-80047
CS-0106633
HY-126653

Research Excerpts

Overview

Atpenin A5 (AA5) is a potent and specific complex II inhibitor. AA5 also activates the mK(ATP) channel and protects against simulated ischemia-reperfusion (IR) injury.

ExcerptReferenceRelevance
"Atpenin A5 (AA5) is a potent and specific complex II inhibitor, and herein we report that AA5 (1 nM) also activates the mK(ATP) channel and protects against simulated ischemia-reperfusion (IR) injury in isolated cardiomyocytes."( The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels.
Brookes, PS; Wojtovich, AP, 2009
)
1.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (2)

PathwayProteinsCompounds
anaerobic energy metabolism (invertebrates, mitochondrial)1342
superpathway of anaerobic energy metabolism (invertebrates)1660

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1202112Inhibition of rat liver SQR2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of N-benzoxazol-5-yl-pyrazole-4-carboxamides as nanomolar SQR inhibitors.
AID1202111Inhibition of bovine heart SQR2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of N-benzoxazol-5-yl-pyrazole-4-carboxamides as nanomolar SQR inhibitors.
AID465212Inhibition of Septoria nodorum sub-mitochondrial membrane SQR assessed as ubiquinol-dependent reduction of DCIP after 10 mins by spectrophotometry2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Synthetic atpenin analogs: Potent mitochondrial inhibitors of mammalian and fungal succinate-ubiquinone oxidoreductase.
AID465211Inhibition of bovine heart sub-mitochondrial membrane SQR assessed as ubiquinol-dependent reduction of DCIP after 10 mins by spectrophotometry2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Synthetic atpenin analogs: Potent mitochondrial inhibitors of mammalian and fungal succinate-ubiquinone oxidoreductase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's1 (6.25)18.2507
2000's4 (25.00)29.6817
2010's10 (62.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.22 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index31.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]